[Therapeutic efficacy of anidulafungin for the treatment of oesophageal candidiasis, candidemia and invasive candidiasis].
Anidulafungin is a new echinocandin that appears to have several advantages over existing antifungals. It is unique because it slowly degrades in humans, undergoing a process of biotransformation rather than being metabolized. It exhibits high in vitro and in vivo activities against Candida spp. and Aspergillus spp. In several clinical studies investigating Candida esophagitis; candidemia and invasive candidiasis, the clinical efficacy of this echinocandin was similar, or even superior, to that of established antifungals in candidemia. Antifungal activity against strains no longer susceptible to conventional antifungal agents, such as fluconazole and amphotericin B suggests that anidulafungin can be used as salvage therapy in life-threatening fungal infections. The limited toxicity profile, minimal drug-drug interactions and the fact that does not require dosage adjustment in subjects with hepatic or renal impairment, establishes this echinocandin as an attractive new option for the treatment of invasive fungal infections.
Montejo González
Juan Carlos
JC
Servicio de Medicina Intensiva, Unidad Polivalente, Hospital Universitario 12 de Octubre, Madrid, Spain. jmontejo.hdoc@salud.madrid.org
Catalán González
Mercedes
M
León Gil
Cristóbal
C
D000077612:Anidulafungin; D000935:Antifungal Agents / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy*; D054714:Echinocandins / Q000627:therapeutic use*; D004941:Esophagitis / Q000188:drug therapy* / Q000382:microbiology*; D016469:Fungemia / Q000188:drug therapy*; D006801:Humans
D000935:Antifungal Agents; D054714:Echinocandins; D000077612:Anidulafungin